In addition, most TEMs co-express the leukocyte marker CD52, which is the target of alemtuzumab, a monoclonal antibody approved by the Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia [17]. This evidence concerns the gene CD52 and B-cell chronic lymphocytic leukemia.